Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV).
Holzhey T, Pönisch W, Wang SY, Holzvogt M, Holzvogt B, Andrea M, Zehrfeld T, Hammerschmidt D, Hoffmann FA, Becker C, Schwarzer A, Schwarz M, Schönfelder-Fricke U, Edelmann T, Braunert L, Franke GN, Jentzsch M, Schwind S, Bill M, Grimm J, Remane Y, Platzbecker U, Scholz M.
Holzhey T, et al. Among authors: platzbecker u.
J Cancer Res Clin Oncol. 2021 Aug;147(8):2349-2359. doi: 10.1007/s00432-020-03504-3. Epub 2021 Jan 12.
J Cancer Res Clin Oncol. 2021.
PMID: 33433659
Free PMC article.